Growth acceleration in children with chronic renal failure treated with growth-hormone-releasing hormone (GHRH).

Pasqualini T, Ferraris J, Fainstein-Day P, Eymann AA, Moyano Caturelly S, Ruiz S, Ramirez J, Gutman R

Medicina1 Jan 1996Cited by 1 (Europe PMC)

PMID9035479PepBankPUB-09035479

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In children with chronic renal failure, 5 of 9 showed improved growth in response to GHRH therapy.
In plain wordsIn children with chronic kidney failure, 5 of 9 grew faster with GHRH treatment.
Peptide
Sermorelin
Outcome
IncreaseProportion with improved growth
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
26 +/- 2.4 micrograms/kg/day · subcutaneous · 3 to 6 monthsAs given in this study (human).
Source sentences
Summary
5 out of 9 short children with CRF, 3 on conservative treatment, 1 on dialysis and 1 post renal transplantation, showed improved growth in response to GHRH therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
Nine children with CRF (3 on conservative treatment; 3 on dialysis and 3 after renal transplantation) aged 1.6 to 14.0 (x +/- SE: 8.1 +/- 1.4) years, were treated with twice daily subcutaneous injections of 26 +/- 2.4 micrograms/kg/day growth-hormone-releasing-hormone [GHRH (1-29) NH2 Serono (Geref)…
Report a problemFND-0903547902
02HumanNon-randomized trialActivity measurement
The peak GH response to GHRH was significantly higher in growth non-responders than in responders.
In plain wordsChildren whose growth did not respond to GHRH had a higher peak GH response to a GHRH test than responders.
Peptide
Sermorelin
Outcome
Not applicablePeak GH response to GHRH test by growth response
Study
n = 9
Comparator
Growth responders
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
26 +/- 2.4 micrograms/kg/day · subcutaneous · 3 to 6 monthsAs given in this study (human).
Source sentences
Summary
The peak GH response to GHRH was significantly higher in the group of growth non-responders than in the responders (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Nine children with CRF (3 on conservative treatment; 3 on dialysis and 3 after renal transplantation) aged 1.6 to 14.0 (x +/- SE: 8.1 +/- 1.4) years, were treated with twice daily subcutaneous injections of 26 +/- 2.4 micrograms/kg/day growth-hormone-releasing-hormone [GHRH (1-29) NH2 Serono (Geref)…
Report a problemFND-0903547903
03HumanNon-randomized trialSafety outcome
In children with chronic renal failure, mean serum urea and creatinine remained stable during GHRH treatment.
In plain wordsIn children with chronic kidney failure, blood urea and creatinine stayed stable during GHRH treatment.
Peptide
Sermorelin
Outcome
No significant changeSerum urea and creatinine
Study
n = 9
Outcome group
Kidney function · Kidney and urinary
Studied dose
26 +/- 2.4 micrograms/kg/day · subcutaneous · 3 to 6 monthsAs given in this study (human).
Source sentences
Summary
Mean serum urea and creatinine remained stable, although 2 patients on conservative treatment showed a moderate increase in serum creatinine.
1 context sentence(design, population, supporting numbers)
Summary · context
Nine children with CRF (3 on conservative treatment; 3 on dialysis and 3 after renal transplantation) aged 1.6 to 14.0 (x +/- SE: 8.1 +/- 1.4) years, were treated with twice daily subcutaneous injections of 26 +/- 2.4 micrograms/kg/day growth-hormone-releasing-hormone [GHRH (1-29) NH2 Serono (Geref)…
Report a problemFND-0903547904
04HumanNon-randomized trialSafety outcome
No consistent effect of GHRH on renal function was detected in children with chronic renal failure.
In plain wordsGHRH treatment had no consistent effect on kidney function in children with chronic kidney failure.
Peptide
Sermorelin
Outcome
No significant changeRenal function
Study
n = 9
Outcome group
Kidney function · Kidney and urinary
Studied dose
26 +/- 2.4 micrograms/kg/day · subcutaneous · 3 to 6 monthsAs given in this study (human).
Source sentences
Summary
No consistent effect on renal function was detected.
1 context sentence(design, population, supporting numbers)
Summary · context
Nine children with CRF (3 on conservative treatment; 3 on dialysis and 3 after renal transplantation) aged 1.6 to 14.0 (x +/- SE: 8.1 +/- 1.4) years, were treated with twice daily subcutaneous injections of 26 +/- 2.4 micrograms/kg/day growth-hormone-releasing-hormone [GHRH (1-29) NH2 Serono (Geref)…
Report a problemFND-0903547905
05HumanNon-randomized trialEfficacy outcome
In 5 children with chronic renal failure, GHRH treatment raised height velocity from 3.8 to 8.0 cm/year.
In plain wordsIn 5 children with chronic kidney failure, GHRH treatment raised growth speed.
Peptide
Sermorelin
Outcome
IncreaseHeight velocity
Study
n = 5
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
26 +/- 2.4 micrograms/kg/day · subcutaneous · 3 to 6 monthsAs given in this study (human).
Measurements
Height velocity
8 cm/year
5 patients after treatment
Source sentences
Summary
Five patients increased height velocity from 3.8 +/- 0.7 to 8.0 +/- 1.2 cm/year (paired t test, p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Nine children with CRF (3 on conservative treatment; 3 on dialysis and 3 after renal transplantation) aged 1.6 to 14.0 (x +/- SE: 8.1 +/- 1.4) years, were treated with twice daily subcutaneous injections of 26 +/- 2.4 micrograms/kg/day growth-hormone-releasing-hormone [GHRH (1-29) NH2 Serono (Geref)…
Report a problemFND-0903547901

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 10:21 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.